BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 11
• 12
• 13
• 14
• 15
• 16
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29

• 

  Policy

  CMS Sends Initial Medicare Drug Price Proposals to Companies

  The Centers for Medicare and Medicaid Services on Thursday sent its opening price proposals to drugmakers, which now have 30 days to either approve the offers or submit counteroffers.

  February 2, 2024

   · 

  3 min read

   · 

  Tristan Manalac
• 

  Deals

  Alto, Fractyl Go Public in Back-to-Back Offerings as IPO Market Heats Up

  Alto Neuroscience and Fractyl Health provided further momentum to the recent spate of biotech initial public offerings, with both companies going public on Friday morning in respective $128 million and $110 million IPOs.

  February 2, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Deals

  Kyverna Looks to Go Public, Raise $182M Amid Surge in Biotech IPOs

  Kyverna Therapeutics, the fifth biotech with plans for an initial public offering this year, will use the proceeds to support the development of its anti-CD19 CAR-T therapies for autoimmune diseases.

  February 2, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Business

  GSK Sees Sales Uptick in 2023 Fueled by Vaccines for RSV and Shingles

  The British pharma expects “meaningful” sales and earnings growth in 2024 and is upgrading its growth outlooks for 2026 and 2031, according to GSK CEO Emma Walmsley.

  February 2, 2024

   · 

  2 min read

   · 

  Tyler Patchen
• 

  Business

  AbbVie Gets Q4 Beat, Sees 2023 Sales Decline in Oncology and Immunology

  While AbbVie beat revenue expectations in the fourth quarter of 2023, the company reported Friday that its overall sales last year declined as it faced biosimilar competition for its blockbuster Humira.

  February 2, 2024

   · 

  2 min read

   · 

  Tyler Patchen
• 

  Business

  Merck Posts $60B in Sales for 2023 Driven by Keytruda, HPV Vaccine

  The company’s blockbuster cancer treatment Keytruda continues to be a significant boon to its bottom line, according to Merck’s fourth quarter and full-year 2023 financial results.

  February 2, 2024

   · 

  1 min read

   · 

  Tyler Patchen
• 

  Drug Delivery

  Drug Pricing Reforms Front and Center as 2024 Election Ramps Up

  The U.S. Department of Health and Human Services on Thursday released new data showing that Americans pay three times more for prescription drugs than other developed countries and nearly 10 times more for insulin.

  February 2, 2024

   · 

  3 min read

   · 

  Greg Slabodkin
• 

  Business

  BMS Tops Q4 Estimates, Looks to New Products and M&A with Exclusivity Loss

  The pharma Friday reported in-line and new product revenue growth of 9%, bringing in $9.8 billion for the fourth quarter of 2023. Eliquis and Opdivo remain top sellers but BMS is facing the loss of exclusivity.

  February 2, 2024

   · 

  2 min read

   · 

  Kate Goodwin
• 

  Vaxcyte Looks to Raise $750M in Latest Public Offering

  As Vaxcyte targets it’s the pneumococcal vaccine market, the company is facing significant competition from major pharma companies already in the space.

  February 2, 2024

   · 

  2 min read

   · 

  Tyler Patchen
• 

  Drug Development

  5 Alzheimer’s Data Readouts to Watch in 2024

  With one disease-modifying therapy already reaching patients and another expected to soon, several biopharma companies anticipate key data for novel assets in the coming 12 months.

  February 2, 2024

   · 

  4 min read

   · 

  Kate Goodwin